ZVSA (ZyVersa) Enterprise Value-to-Revenue Multiple

ZyVersa (ZVSA) - corporate logo

A strategic alliance with research centers strengthens the credit potential of ZyVersa Therapeutics (ZVSA). The EV/Sales multiple trajectory on the GURU.Markets chart demonstrates stability, where the mark reflects the latest data. Financial stability is based on nephropathy and chronic inflammation therapies, while operational reliability is guaranteed by a diversified raw material supply system and established inventory reserves.

ZyVersa (ZVSA) - EV/Sales Multiple from 07/04/2022 to 11/20/2026

ZVSA (ZyVersa Therapeutics Inc.): analytical breakdowns and indicator data

Fundamental company valuation:ZVSA - ZyVersa Therapeutics
Product sample of ZyVersa Therapeutics, Inc.

This indicator determines the enterprise value of the business, accounting for net debt, and compares it to the volume of generated sales to identify asset overvaluation. By analyzing the EV/Revenue ratio, an investor assesses the efficiency of the ZyVersa Therapeutics (ZVSA) model, where the absence of proprietary manufacturing plants and a reliance on outsourcing make this coefficient a key measure of intellectual property value relative to operating revenues.